Urothelial tumor initiation requires deregulation of multiple signaling pathways: Implications in target-based therapies

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 770-780

  Zhou, Haiping ^a   Huang, Hong Ying ^a   Shapiro, Ellen ^a   Lepor, Herbert ^a   Huang, William C ^a   Mohammadi, Moosa ^a   Mohr, Ian ^a   Tang, Moon Shong ^a   Huang, Chuanshu ^a   Wu, Xue Ru ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; RAS PROTEIN; SIMIAN VIRUS 40 T ANTIGEN; STAT3 PROTEIN; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER UROTHELIAL CARCINOMA; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HYPERPLASIA; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

EID: 84859601315     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs025     Document Type: Article

References (89)

1. American Cancer Society. (2011) Cancer Facts and Figures 2011. American Cancer Society, Atlanta, GA.
2. Parkin, D. M. et al. (2001) Estimating the world cancer burden: Globocan 2000. Int. J. Cancer, 94, 153-156.
3. Ploeg, M. et al. (2009) The present and future burden of urinary bladder cancer in the world. World J. Urol., 27, 289-293.
4. McConkey, D. J. et al. (2010) Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol. Oncol., 28, 429-440.
5. Goebell, P. J. et al. (2010) Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol., 28, 409-428.
6. Castillo-Martin, M. et al. (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol., 28, 401-408.
7. Wolff, E. M. et al. (2005) Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat. Clin. Pract. Urol., 2, 502-510.
8. Mitra, A. P. et al. (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu. Rev. Pathol., 4, 251-285.
9. Cohen, S. M. (2002) Comparative pathology of proliferative lesions of the urinary bladder. Toxicol. Pathol., 30, 663-671.
10. Dinney, C. P. et al. (2004) Focus on bladder cancer. Cancer Cell, 6, 111-116.
11. Dalbagni, G. (2007) The management of superficial bladder cancer. Nat. Clin. Pract. Urol., 4, 254-260.
12. Grossman, H. B. (1996) Superficial bladder cancer: decreasing the risk of recurrence. Oncology (Huntingt), 10, 1617-1624; discussion 1624, 1627-1628.
13. Hodges, K. B. et al. (2010) Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum. Pathol., 41, 155-162.
14. van Oers, J. M. et al. (2006) Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int. J. Cancer, 119, 1212-1215.
15. Pollard, C. et al. (2010) Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev. Mol. Med., 12, e10.
16. Wu, X. R. (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer, 5, 713-725.
17. Knowles, M. A. (2007) Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J. Urol., 25, 581-593.
18. van Rhijn, B. W. et al. (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res., 64, 1911-1914.
19. Bakkar, A. A. et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res., 63, 8108-8112.
20. Platt, F. M. et al. (2009) Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin. Cancer Res., 15, 6008-6017.
21. Boulalas, I. et al. (2009) Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. Int. J. Biol. Markers, 24, 17-21.
22. Jebar, A. H. et al. (2005) FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 24, 5218-5225.
23. Sandberg, A. A. et al. (1994) Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J. Urol., 151, 545-560.
24. Aveyard, J. S. et al. (2004) Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification. J. Mol. Diagn., 6, 356-365.
25. Cordon-Cardo, C. et al. (2000) Genetic and molecular markers of urothelial premalignancy and malignancy. Scand. J. Urol. Nephrol. Suppl., 205, 82-93.
26. O'Connor, R. C. et al. (2001) Therapeutic options and treatment of muscle invasive bladder cancer. Expert Rev. Anticancer Ther., 1, 511-522.
27. Lee, C. T. et al. (2007) Treatment of muscle-invasive bladder cancer: is cystectomy enough? Nat. Clin. Pract. Urol., 4, 126-127.
28. Chang, S. S. et al. (2005) Radical cystectomy for bladder cancer: the case for early intervention. Urol. Clin. North Am., 32, 147-155.
29. Lotan, Y. et al. (2009) Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer, 115, 4096-4103.
30. Koss, L. G. (1998) Natural history and patterns of invasive cancer of the bladder. Eur. Urol., 33, 2-4.
31. Koss, L. G. (1992) Bladder cancer from a perspective of 40 years. J. Cell. Biochem. Suppl., 16I, 23-29.
32. Cordon-Cardo, C. (2004) p53 and Rb: simple interesting correlates or tumor markers of critical predictive nature? J. Clin. Oncol., 22, 975-977.
33. Grossman, H. B. et al. (1998) p53 and Rb expression predict progression in T1 bladder cancer. Clin. Cancer Res., 4, 829-834.
34. Cordon-Cardo, C. et al. (1997) Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res., 57, 1217-1221.
35. Cote, R. J. et al. (1998) Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res., 58, 1090-1094.
36. Knowles, M. A. (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, 27, 361-373.
37. Zhao, J. et al. (1999) Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res., 59, 4658-4661.
38. Zhang, Z. T. et al. (2001) Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene, 20, 1973-1980.
39. Mo, L. et al. (2007) Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J. Clin. Invest., 117, 314-325.
40. Zhang, Z. T. et al. (1999) Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res., 59, 3512-3517.
41. Cheng, J. et al. (2003) Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res., 63, 179-185.
42. Puzio-Kuter, A. M. et al. (2009) Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev., 23, 675-680.
43. Shankaranarayanan, P. et al. (2009) Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell, 16, 220-231.
44. Siddiquee, K. et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl Acad. Sci. USA, 104, 7391-7396.
45. Benedict, W. F. et al. (1999) Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene, 18, 1197-1203.
46. Chatterjee, S. J. et al. (2004) Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J. Pathol., 203, 762-770.
47. Shariat, S. F. et al. (2004) p53, p21, pRb, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol., 22, 1014-1024.
48. Rabbani, F. et al. (2000) Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol. Clin. North Am., 27, 83-102, ix.
49. Wu, X. R. (2009) Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev., 28, 281-290.
50. Sherr, C. J. (2001) The INK4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol., 2, 731-737.
51. Ahuja, D. et al. (2005) SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene, 24, 7729-7745.
52. Kurzrock, E. A. et al. (2008) Label-retaining cells of the bladder: candidate urothelial stem cells. Am. J. Physiol. Renal Physiol., 294, F1415-F1421.
53. Farassati, F. et al. (2008) Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am. J. Pathol., 173, 1861-1872.
54. Grammatikakis, N. et al. (2001) Simian virus 40 large tumor antigen modulates the Raf signaling pathway. J. Biol. Chem., 276, 27840-27845.
55. Lee, G. H. et al. (1990) Detection of activated c-H-ras oncogene in hepatocellular carcinomas developing in transgenic mice harboring albumin promoter-regulated simian virus 40 gene. Carcinogenesis, 11, 1145-1148.
56. Tack, L. C. et al. (1989) The p53 complex from monkey cells modulates the biochemical activities of simian virus 40 large T antigen. J. Virol., 63, 1310-1317.
57. Cully, M. et al. (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 6, 184-192.
58. O'Reilly, K. E. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 66, 1500-1508.
59. Wu, X. et al. (2010) PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes. Biochem. Biophys. Res. Commun., 393, 514-518.
60. Podsypanina, K. et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc. Natl Acad. Sci. USA, 98, 10320-10325.
61. Zeng, Z. et al. (2007) Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood, 109, 3509-3512.
62. Anderl, S. et al. (2011) Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum. Mol. Genet., 20, 4597-4604.
63. Cuenda, A. et al. (1999) Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem., 274, 4341-4346.
64. Oh, C. D. et al. (2001) Immunosuppressant rapamycin inhibits protein kinase C alpha and p38 mitogen-activated protein kinase leading to the inhibition of chondrogenesis. Eur. J. Pharmacol., 427, 175-185.
65. Ahmad, I. et al. (2011) K-Ras and {beta}-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis. Model Mech., 4, 548-555.
66. Gao, J. et al. (2004) p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Oncogene, 23, 687-696.
67. Logie, A. et al. (2005) Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet., 14, 1153-1160.
68. Cheng, J. et al. (2002) Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res., 62, 4157-4163.
69. Ornitz, D. M. et al. (2001) Fibroblast growth factors. Genome Biol., 2: reviews3005-reviews3005. 12.
70. Tsantoulis, P. K. et al. (2008) Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene, 27, 3256-3264.
71. Efeyan, A. et al. (2007) p53: guardian of the genome and policeman of the oncogenes. Cell Cycle, 6, 1006-1010.
72. Negrini, S. et al. (2010) Genomic instability-an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol., 11, 220-228.
73. Halazonetis, T. D. et al. (2008) An oncogene-induced DNA damage model for cancer development. Science, 319, 1352-1355.
74. Mayo, L. D. et al. (2002) The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci., 27, 462-467.
75. Tamguney, T. et al. (2007) New insights into PTEN. J. Cell Sci., 120, 4071-4079.
76. Robinson, J. P. et al. (2010) Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene, 29, 335-344.
77. Robinson, J. P. et al. (2011) Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene, 30, 1341-1350.
78. Thorstenson, A. et al. (2010) Diagnostic random bladder biopsies: reflections from a population-based cohort of 538 patients. Scand. J. Urol. Nephrol., 44, 11-19.
79. Hansel, D. E. et al. (2010) Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am. J. Pathol., 176, 3062-3072.
80. Knowles, M. A. et al. (2009) Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev., 28, 305-316.
81. Schultz, L. et al. (2010) Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer, 116, 5517-5526.
82. Ching, C. B. et al. (2010) Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Lab. Invest., 90, 1406-1414.
83. Makhlin, I. et al. (2011) The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int., 108, E84-E90.
84. Chiong, E. et al. (2011) Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin. Cancer Res., 17, 2863-2873.
85. Metalli, D. et al. (2010) The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogenactivated protein kinase-dependent activation of paxillin. Am. J. Pathol., 176, 2997-3006.
86. Dangle, P. P. et al. (2009) Ras-MAPK pathway as a therapeutic target in cancer-emphasis on bladder cancer. Recent Pat. Anticancer Drug Discov., 4, 125-136.
87. Kumar, B. et al. (2009) Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells. Int. J. Oncol., 34, 1557-1564.
88. Chen, C. L. et al. (2008) Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol. Cancer, 7, 78.
89. Mitra, A. P. et al. (2009) Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol., 27, 3929-3937.